医学
代理终结点
临床终点
新辅助治疗
肿瘤科
化疗
内科学
临床试验
病态的
肺癌
病理分期
肺
癌症
乳腺癌
作者
Matthew David Hellmann,Jamie E. Chaft,William N. William,Valerie W. Rusch,Katherine M.W. Pisters,Neda Kalhor,Apar Pataer,William David Travis,Stephen G. Swisher,Mark G. Kris
出处
期刊:Lancet Oncology
[Elsevier BV]
日期:2014-01-01
卷期号:15 (1): e42-e50
被引量:654
标识
DOI:10.1016/s1470-2045(13)70334-6
摘要
Improvements in outcomes for patients with resectable lung cancers have plateaued. Clinical trials of resectable non-small-cell lung cancers with overall survival as the primary endpoint require a decade or longer to complete, are expensive, and limit innovation. A surrogate for survival, such as pathological response to neoadjuvant chemotherapy, has the potential to improve the efficiency of trials and expedite advances. 10% or less residual viable tumour after neoadjuvant chemotherapy, termed here major pathological response, meets criteria for a surrogate; major pathological response strongly associates with improved survival, is reflective of treatment effect, and captures the magnitude of the treatment benefit on survival. We support the incorporation of major pathological response as a surrogate endpoint for survival in future neoadjuvant trials of resectable lung cancers. Additional prospective studies are needed to confirm the validity and reproducibility of major pathological response within individual histological and molecular subgroups and with new drugs.
科研通智能强力驱动
Strongly Powered by AbleSci AI